Skip to main content

Table 2 Adverse events by study group

From: Phase 1 safety and tolerability study of BMP-7 in symptomatic knee osteoarthritis

  0.03 mg
(N = 7)
0.1 mg
(N = 6)
0.3 mg
(N = 6)
1 mg
(N = 6)
Placebo
(N = 8)
Number of Patients with at least one AE 7 (100%) 5 (83.3%) 5 (83.3%) 6 (100%) 7 (87.5%)
Number of Patients with no AE 0 (0%) 1 (16.7%) 1 (16.7%) 0 (0%) 1 (12.5%)
Arthralagia 4 (57.1%) 1 (16.7%) 5 (83.3%) 5 (83.3%) 6 (75%)
Nasopharyngitis 2 (28.6%) 2 (33.3%) 1 (16.7%) 0 (0%) 1 (12.5%)
Upper Respiratory Tract Infection 1 (14.3%) 0 (0%) 3 (50%) 1 (16.7%) 1 (12.5%)
Headache 1 (14.3%) 2 (33.3%) 2 (33.3%) 0 (0%) 1 (12.5%)
Influenza 0 (0%) 2 (33.3%) 0 (0%) 0 (0%) 2 (25%)
Joint Stiffness 2 (28.6%) 1 (16.7%) 1 (16.7%) 0 (0%) 1 (12.5%)
Joint Swelling 2 (28.6%) 0 (0%) 0 (0%) 1 (16.7%) 0 (0%)
Lymphadenopathy 0 (0%) 1 (16.7%) 0 (0%) 1 (16.7%) 0 (0%)
Injection Site Bruising 0 (0%) 2 (33.3%) 0 (0%) 0 (0%) 0 (0%)
Injection Site Pain 1 (14.3%) 0 (0%) 0 (0%) 4 (66.7%) 1 (12.5%)
Injection Site Mass 0 (0%) 1 (16.7%) 0 (0%) 1 (16.7%) 0 (0%)
Injection Site Swelling 1 (14.3%) 0 (0%) 1 (16.7%) 1 (16.7%) 0 (0%)